Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Patent Protection
Pharma
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Pfizer is pulling the trigger on the full transition to Vyndamax as Vyndaqel is expected to lose patent protection in 2028.
Angus Liu
Aug 29, 2025 10:40am
Roche's high-dose version of Ocrevus flunks phase 3 trial
Apr 2, 2025 3:26pm
Teva hit with €463M fine over Copaxone misconduct claims in EU
Oct 31, 2024 10:45am
Drugmakers dig in their heels amid FTC's latest patent crackdown
Jun 25, 2024 9:20am
FTC targets Novo's Ozempic among 300-plus 'junk' patents
May 1, 2024 7:30am
Lawmakers blast Biden administration's 'march-in' proposal
Feb 23, 2024 9:53am
